BLUE SAIL MEDICAL CO.,LTD.
蓝帆医疗
002382
Shenzhen Stock Exchange
Company Profile
1. The company has established an industrial layout integrating high-value and low-value products, with each business segment having a leading position in global competition. Focusing on the medical device field, the company has delved into vertical niche markets and built a multi-business segment layout featuring complementary models and risk hedging through the combination of high-value and low-value consumables. After years of transformation and upgrading, it has evolved from a low-value consumables enterprise mainly producing medical gloves to a leading medical device company covering areas such as cardiovascular and cerebrovascular, health protection, and emergency rescue. 2. The company's outstanding product innovation capabilities have established a platform-based matrix of existing products and R&D pipelines, laying a solid foundation for long-term performance growth. (1) Cardiovascular and Cerebrovascular Division: The company consistently launches new products, driving the entry of regular products into hospitals with blockbuster products and promoting rapid business growth with innovative products. It has deeply engaged in areas such as coronary intervention and structural heart diseases, maintaining high-level and efficient R&D investment, and has formed a high-quality R&D pipeline. (2) Health Protection Division: The company has been deeply involved in the health protection field for many years. In the first half of 2025, it added new products such as medical examination gloves and low-zinc food-grade nitrile gloves. Blue帆Medical has been recognized as a provincial manufacturing single champion； its subsidiary， Shandong Health Technology， has received multiple honors and awards including high-tech enterprise， contribution award for scientific and technological innovation development， and contribution award for key project construction； its subsidiary， Shandong Blue帆New Materials Co.， Ltd.， has been recognized as a high-tech enterprise. (3) Emergency Rescue Division： The company's emergency rescue products mainly consist of first aid kits and bags， which have obtained EU CE certificates， MDSAP certificates from Australia and Canada， and FDA certifications from the United States. Its subsidiary， Hubei Gaode， has received multiple honors and certifications including high-tech enterprise， provincial specialized， refined， distinctive， and innovative small and medium-sized enterprise， provincial high-quality development enterprise， provincial green manufacturing factory， and 2024 provincial manufacturing single champion enterprise. The company continuously optimizes first aid kit products， developing more humanized， efficient， creative， and scene-specific emergency rescue products to enhance the richness of its product line. (4) External Investment and Incubation Field： In the cardiovascular and cerebrovascular field， the company has extended its layout through equity participation in products such as ventricular assist devices (VAD) and optical coherence tomography (OCT)， and has invested and incubated in related tracks such as neurointervention and peripheral intervention. This is aimed at continuously enhancing the company's comprehensive competitive strength in high-value cardiovascular and cerebrovascular consumables， improving the cross-segment market platformization capabilities of the cardiovascular and cerebrovascular division， and building a solid product innovation barrier. As of June 30， 2025， the company's incubated neurointervention business segment has had 7 products approved， and the company's incubated peripheral intervention business segment has had 6 products approved. 3. The company's ability to gather global top resources for R&D has achieved internationally leading technological R&D capabilities， helping the company build long-term technological barriers. (1) Global collaborative R&D， building a 24-hour two-way interactive innovation system： The company has established R&D and clinical registration platforms in multiple core regions around the world， with over 540 patents. Relying on global R&D resources， clinical data from top hospitals at home and abroad， and the practical experience of the domestic R&D team， it has established a two-way interactive R&D mechanism between international and domestic. This mechanism not only introduces overseas technologies but also promotes Chinese independent technologies to go global， forming an innovative model of coordinated development between internationalization and localization. (2) Leading innovation research in the industry， with global recognition of technology and academic influence： The company is a medical device enterprise with complete independent intellectual property rights in the cardiovascular and cerebrovascular field in China. Its core technologies， products， and clinical achievements have been published in multiple top international academic journals and widely recognized by the industry. (3) Always adhering to innovation-driven high-quality development， committed to creating new quality productivity. After 20 years of development, the company has grown into a multinational platform enterprise with globalized R&D, clinical trials, manufacturing, and internationalized talents, focusing on the strategic emerging industry of high-end medical devices and integrating high-tech attributes into its manufacturing genes. 4. A global customer base and sales coverage, along with channel reuse among various sub-sectors, promote business growth while mitigating external risks. The company has implemented a global localization strategy, combining direct sales and distribution, offline and online sales, and adopting efficient market access, innovative marketing, and multi-channel cooperation to build an industry-leading sales network. Leveraging its "high-value + low-value" integrated medical device industrial platform, it has successfully achieved cross-industry collaborative sales. Through resource sharing and complementary advantages among various business units, it provides customers with one-stop surgical instruments and consumables products and solutions, continuously enhancing customer loyalty. 5. Localized production in multiple regions worldwide, insistence on autonomous and controllable supply chains, and continuous integration and optimization of production facilities lay a solid foundation for profit growth. The cardiovascular division has fully localized its international business production overseas, with coronary products manufactured in Singapore and structural heart disease products produced in Germany and Singapore. This enables independent production and supply in China, Europe, and Southeast Asia, effectively addressing potential trade protectionism in various countries and ensuring supply chain stability. The health protection and emergency rescue divisions have continuously improved production technology and integrated production capacity, achieving sustained efficiency improvements and lean, low-cost operations. 6. The core corporate culture of "openness, inclusiveness, standardization, and co-creation" attracts global talents and partners, facilitating long-term and sustainable development. The company adheres to the new era of socialism with Chinese characteristics, drawing wisdom from traditional Chinese culture and Shandong Qi culture to cultivate a distinctive Blue帆 Medical corporate culture： "openness， inclusiveness， standardization， and co-creation". The core management team has long been engaged in related industries， possessing profound industry technical and development insight capabilities.
Full description
BlueSail Medical Co., Ltd. (referred to as "BlueSail Medical") was established in 2002 and successfully listed on the Shenzhen Stock Exchange on April 2, 2010 (stock code: 002382). It is a leading multinational medical device company with a complete layout of high-value and medium-low value consumables. After years of operation and development, the company has built a multi-business sector layout featuring complementary and risk-hedging models of high-value and low-value consumables, mainly including: (1) Cardiovascular business, with stents, balloons and heart valves as the core, comprehensively covering implantable and interventional devices; (2) Health protection business, with disposable gloves as the core, comprehensively covering multiple application scenarios such as medical, industrial and catering, and offering a full range of gloves including PVC, nitrile, latex, TPE/CPE and polyurethane; (3) Emergency rescue business, with first aid kits as the core, comprehensively covering emergency equipment, single items and emergency services. (1) Cardiovascular business The company's cardiovascular division is mainly engaged in the research and development, production and sales of medical devices related to coronary intervention and structural heart diseases. The company fully leverages its independent research and development capabilities and its globally exclusive patented drug Biolimus A9® (hereinafter referred to as "BA9™"), and through leading technology of drug-device combination, independently researches and develops differentiated and leading coronary stents, balloons and other medical devices. (2) Health protection business The health protection business centered on disposable gloves is the company's traditional strength business. It is the first listed company in the industry to complete the full range layout of disposable gloves and can provide customers with the most complete product series. During the reporting period, the company developed new products such as medical examination gloves and low-zinc food-grade nitrile gloves on the basis of traditional applications of gloves, and achieved mass production and application of a large number of new function, new application and new index products such as disposable medical rubber examination gloves, strong and durable black polymer nitrile gloves and 16-inch extra-long household gloves, enriching the product structure and extending the product category, further strengthening the company's position as the first listed company in the industry to complete the full range layout of disposable gloves. (3) Emergency rescue business The current main business is the research and development, production and sales of various emergency rescue products and disposable health protection products centered on first aid kits. In the domestic first aid kit market, the subsidiary Wuhan Bicare is one of the earliest enterprises to introduce the first aid concept and technology from the international market. It has product layouts and market coverage in various fields and scenarios such as household, vehicle, public places, outdoor, travel, pets and protection. In the European and American first aid kit markets, the products are mainly vehicle first aid kits and industrial first aid kits. The company has won wide customer trust and market recognition with its high-quality products. During the reporting period, the company continued to increase investment in automation research and development, constantly upgraded the production process and packaging methods of first aid kit configuration products, replaced manual operations with automated operations, participated in the writing of industry standards for vehicle emergency kits and household emergency kits, and achieved industry breakthroughs through technological transformation. The company's emergency rescue division continued to deepen and innovate, and its subsidiary Hubei Gaode First Aid and Protective Products Co., Ltd. was awarded the title of "Specialized, Refined, Unique and Innovative Small and Medium-sized Enterprise" during the reporting period, further consolidating the company's leading position in the domestic first aid and protection field. The company has built a medical emergency rescue industrial park in Tuangfeng County, Hubei Province, and constructed an intelligent and lean smart factory, breaking through some key industrial chain bottlenecks, completing the self-production and supply chain integration of some single items, and creating a combination of medical basic materials and emergency care products. The company's subsidiary Hubei Gaode has formed long-term strategic cooperation with German car manufacturers such as Mercedes-Benz, BMW and Audi, as well as French Renault. Under the trend of the expanding scale of China's auto exports, especially the favorable situation of new energy vehicle exports, the company seized the opportunity to actively explore the market for emergency kits for exported new energy vehicles. It has passed the audits of many domestic auto manufacturers and key international customers, and has reached cooperation with several well-known automakers. At the same time, it has also established strategic partnerships with Didi Chuxing, China Merchants Bank, China Life Insurance, Ping An Insurance, and Pacific Insurance, providing them with customized emergency kit solutions. In the future, the company will continue to focus on the mid-to-high-end B-end markets both domestically and internationally, meeting the growing demands and injecting strong impetus into its performance. (4) New Marketing Business The company actively explores and consolidates the market related to the health industry. Through cooperation with third-party testing channels, laboratory channels, food and catering channels, and supermarket channels, it has built a new marketing system with multiple business forms. During the reporting period, the company added over 260 new customers. It continued its strategy of extending to the terminal through multi-platform cooperation. On the basis of the new e-commerce sales models such as "live-streaming sales" and "video sales", it increased cooperation with channels like WeChat Video, Zhenkunxing, and Meituan, precisely reaching a wide range of consumers based on the characteristics of each platform, significantly enhancing product exposure and sales conversion rates. The company also linked offline channels and private domain businesses through its own resources to enhance brand loyalty and customer stickiness.